IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Among a cohort of 1,135 women ages 40 and younger with stage I through III breast cancer, the incidence of LRR was 5.6%, with ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

SWX:NOVN Earnings and Revenue History July 24th 2025 The Impact Of Unusual Items On Profit. To properly understand Novartis' profit results, we need to consider the US$2.8b expens ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...